The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

The Tobias and Lechleiter families donated $20 million to establish the Institute for Clinical Innovation at IU Health, the largest gift in its history.

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

The Tobias-Lechleiter Institute will focus on getting more Hoosiers enrolled in clinical trials and advancing medical ...

The Tobias-Lechleiter Institute for Clinical Innovation will serve as a hub for "groundbreaking" disease detection and ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...

By Nancy Lapid (Reuters) -Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the ...

Despite his age and an ominous-sounding disease, former President Joe Biden has reason for optimism about his aggressive ...